Mark Laws
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
-
- Cancer therapeutics and mechanisms 2
- Phenothiazines and Benzothiazines Synthesis and Activities 2
-
- Antibiotics Pharmacokinetics and Efficacy 3
- Co-authors
- Khondaker Miraz Rahman (12 shared papers)Md. Mahbub Hasan (2 shared papers)Jamshed Iqbal (2 shared papers)Syed Jawad Ali Shah (2 shared papers)Zahid Shafiq (2 shared papers)Shirin Jamshidi (3 shared papers)Charlotte K. Hind (3 shared papers)Melanie Clifford (2 shared papers)
- Journals
- ACS Omega (3 papers)Scientific Reports (1 paper)FEMS Microbiology Reviews (1 paper)Drug Discovery Today (1 paper)Current Medicinal Chemistry (1 paper)
- Partner nations
- United KingdomPakistanSaudi Arabia
In The Last Decade
Mark Laws
10 papers receiving 504 citations
Mark Laws's Hit Papers
Peers
Comparison fields: 5 of 81
- Molecular Medicine 124
- Applied Microbiology and Biotechnology 37
- Microbiology 39
- Drug Discovery 1
- Oncology 137
Countries citing papers authored by Mark Laws
This map shows the geographic impact of Mark Laws's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laws with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laws more than expected).
Fields of papers citing papers by Mark Laws
This network shows the impact of papers produced by Mark Laws. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laws. The network helps show where Mark Laws may publish in the future.
Co-authors
The 17 scholars most cited alongside Mark Laws, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 230 | |
| 2 | Antibody–Drug Conjugates—A Tutorial Review Hit paper breakdown → | 2021 | 167 |
| 3 | 2021 | 50 | |
| 4 | 2022 | 17 | |
| 5 | 2021 | 17 | |
| 6 | 2022 | 11 | |
| 7 | 2020 | 9 | |
| 8 | 2019 | 9 | |
| 9 | 2020 | 5 | |
| 10 | 2025 | 3 | |
| 11 | 2020 | 0 | |
| 12 | 2025 | 0 |
About Mark Laws
Mark Laws is a scholar working on Molecular Biology, Pharmacology, Infectious Diseases, Molecular Medicine and Organic Chemistry, having authored 12 papers that have together received 518 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (3 papers), Antibiotic Resistance in Bacteria (3 papers), Cancer therapeutics and mechanisms (2 papers), Eicosanoids and Hypertension Pharmacology (2 papers), HER2/EGFR in Cancer Research (2 papers), CAR-T cell therapy research (2 papers), Phenothiazines and Benzothiazines Synthesis and Activities (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Molecular Medicine (124 citations), Applied Microbiology and Biotechnology (37 citations), Microbiology (39 citations), Drug Discovery (1 citation) and Oncology (137 citations). Mark Laws has collaborated with scholars based in United Kingdom, Pakistan and Saudi Arabia. Frequent co-authors include Khondaker Miraz Rahman, Md. Mahbub Hasan, Jamshed Iqbal, Syed Jawad Ali Shah, Zahid Shafiq, Shirin Jamshidi, Charlotte K. Hind, Melanie Clifford, Rima D. Alharthy and Rose E. Jeeves. Their work appears in journals such as ACS Omega, Scientific Reports, FEMS Microbiology Reviews, Drug Discovery Today and Current Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.